Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia

Inclusion Criteria:

The patient must have AML that falls into one of the following categories:

AML in 1st complete remission (CR) with intermediate or high risk of relapse following conventional therapy; at least, one of the following features is needed:

Patient required more than one cycle of induction to achieve first CR
White blood cell count (WBC) > 100,000/mm^3 at diagnosis
Any of the following cytogenetic abnormalities: inv (3), t(3:3), del (5q) or -5, 11q23, del(7q) or -7, del (20q) or -20, abnormal 12p, +11 or t8
Any other abnormalities or combination of abnormalities which would predict intermediate or high risk of relapse
AML beyond first CR
Any patient with an identical twin donor who also meets the criteria above
Patients with AML in 1st CR should receive at least two cycles of consolidation chemotherapy prior to mobilization and transplant
Patients must have an adequate number of stem cells previously collected (i.e., > 2 x 10^8 total nucleated cell [TNC] of bone marrow [BM]/kg or 4 x 10^6 [CD]34+ PBSC/kg, unless approved otherwise by Dr. Holmberg); prior to stem cell collection patients must be documented to be in remission and to have received two cycles of consolidation therapy after induction therapy
Pre-Study tests have been performed
Patient must sign an institutional review board (IRB) approved informed consent, conforming with federal and institutional guidelines

Exclusion Criteria:

Patients with good risk AML defined by cytogenetic evaluation with these abnormalities: inversion 16 or t8;21
Patient's life expectancy is severely limited by diseases other than AML
Patient is human immunodeficiency virus (HIV) seropositive
Patient is pregnant
Patient's creatinine > 2.0 mg/dl
Patient's total bilirubin > 2.0 mg/dl (unless Gilbert's disease)
Or serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) >= 2.5 x upper limit of normal (ULN) not due to leukemia
Patient has a history of congestive heart failure, uncontrolled arrhythmias or left ventricular ejection fraction (LVEF) < 50%
Patient has an unrelated human leukocyte antigen (HLA) matched donor and is eligible for a higher priority Fred Hutchinson Cancer Research Center (FHCRC) protocol (for FHCRC patients only)
Patient has an HLA matched or one antigen mismatch family donor available
Patients with a significant active infection that precludes transplant
Patients with a Karnofsky Performance Score less than 70